# US 2006/0039989 A1 · Pharmaceutical compositions of cell lysate and processes for the production and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0039989 A1
- Document ID: US20060039989A1
- Status: Published application
- Kind: A1
- Application number: 10/537,301
- Filed: 2003-11-25
- Published: 2006-02-23
- Earliest claimed: 2002-12-03
- Assignees: Innogenetics N.V.
- Inventors: Chris Vervaet; Jean-Paul Remon; Bernard Delaey; Peter De Waele
- Web page: https://patentgrep.com/patent/US20060039989A1

## CPC

- A61K 9/2009: {Inorganic compounds}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 26/0023: {Polysaccharides}
- A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 26/0085: {Porous materials, e.g. foams or sponges}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.

## Claims

### Claim 1

A pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant and/or antisedimentation agent is xanthan gum.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antiflocculant and /or antisedimentation agent is a combination of xanthan gum and maltodextrin.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition of claim 1 or 2 further comprising a buffering agent.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1 in a dried form.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1 in a freeze-dried form.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cell lysate is a keratinocyte cell lysate.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition further comprises at least one of a pharmaceutically acceptable carrier, excipient and vehicle.

### Claim 8 (depends on 1)

A method of promoting wound healing comprising applying the composition of claim 1 to an area skin in need of said promoting.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7 wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix.

### Claim 11

A process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture, wherein the antiflocculant/antisedimentation agent is xanthan gum.

### Claim 12 (depends on 11)

A process of claim 11 wherein drying the cells is by freeze-drying.

### Claim 13 (depends on 11)

A process of claim 11, wherein cell the lysate is a keratinocyte cell lysate.

### Claim 14 (depends on 11)

A process of claim 11 wherein the antiflocculant and/or antisendimentation agent is a combination of xanthan gum and maltodextrin.

### Claim 15 (depends on 8)

The method of claim 8 wherein said wound is at least one of a wound and a skin ulcer.

### Claim 16 (depends on 8)

The method of claim 8 wherein said composition is in the form of a dry powder, a suspension or a solution.

### Claim 17 (depends on 8)

The method of claim pharmaceutical composition of claim 8 wherein said composition is in the form of a gel, a cream, an ointment or a biocompatible matrix.
